Threshold Pharmaceuticals Inc. (Nasdaq: THLD) reported disappointing interim data from two Phase 2 proof-of-concept clinical trials of tarloxotinib. The stock price tumbled 50 cents to close at $0.68.
Threshold Pharmaceuticals reports disappointing interim data
September 30, 2016 at 18:56 PM EDT
